1042673-20-0
Chemical Structure
JH-I-25
- CAS No.: 1042673-20-0
- Formula:C20H21N5O3
- Molecular Weight:379.42
IUPAC Name: N-(2-methoxy-4-morpholinophenyl)-6-(1H-pyrazol-3-yl)picolinamide
InChIKey: RAFFLDOJXQAJPF-UHFFFAOYSA-N
SMILES: O=C(NC1=CC=C(C=C1OC)N2CCOCC2)C3=NC(=CC=C3)C4=NNC=C4
Biological Activity: JH-I-25 is an orally active IRAK1 and IRAK4 inhibitor. JH-I-25 inhibits LPS-induced IRAK4 phosphorylation, IRAK1 degradation, MAPK activation, and the expression of proinflammatory cytokines TNF-α and IL-6 in lung tissues. JH-I-25 improves the survival rate of LPS-induced septic mice and serves as an IRAK4 recruiter in the design of proteolysis-targeting chimeric molecules. JH-I-25 can be used in research related to diffuse large B-cell lymphoma, Waldenström's macroglobulinemia, septic shock, rheumatoid arthritis, atherosclerosis, Alzheimer's disease, acute lung injury, sepsis, and psoriasis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
JH-I-25 | JH-I-25 is an orally active IRAK1 and IRAK4 inhibitor. JH-I-25 inhibits LPS-induced IRAK4 phosphorylation, IRAK1 degradation, MAPK activation, and the expression of proinflammatory cytokines TNF-α and IL-6 in lung tissues. JH-I-25 improves the survival rate of LPS-induced septic mice and serves as an IRAK4 recruiter in the design of proteolysis-targeting chimeric molecules. JH-I-25 can be used in research related to diffuse large B-cell lymphoma, Waldenström's macroglobulinemia, septic shock, rheumatoid arthritis, atherosclerosis, Alzheimer's disease, acute lung injury, sepsis, and psoriasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang L, et al. Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). The Journal of biological chemistry. 2019 Mar 22;294(12):4511-4519. [Content Brief]
- [2]. Ye B, et al. Degradation of IRAK4 for the treatment of lipopolysaccharide-induced acute lung injury in mice. Frontiers in pharmacology. 2025;16:1609923.
- [3]. Chen L, et al. Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases. Journal of medicinal chemistry. 2024 May 23;67(10):8060-8076. [Content Brief]
